

11 October 2018

ASX Code: MXC

CannEpiTM available for Australian supply under Authorised Prescriber Scheme

First commercial-scale production and material revenues to commence from MXC Investigational Medicinal Product (IMP)

A
S
X

R
E
L
E
A
S
E

- MXC’s Medicinal Cannabis based IMP, CannEpiTM is now available for supply in Australia under the Authorised Prescriber Scheme
- Authorisation has been granted by the TGA to specialist prescribers who are now authorised to supply CannEpiTM to patients in Australia
- Authorisation follows recent Human Research Ethics Committee endorsement from St Vincent’s Hospital Melbourne for the use of CannEpiTM in the treatment of adult patients with drug-resistant epilepsy
- Represents a major milestone for MXC, validating and confirming its seed-to-pharma strategy with the start of commercial supply of its first IMP offering
- The Company expects this to initially generate \$1 million in annualised revenue from the initial base of approximately 100 patients
- CannEpiTM is expected to be available for supply in Australia by December 2018

MGC Pharmaceuticals Ltd (ASX: MXC or “the Company”) is pleased to announce the receipt of formal authorisation for the availability of its product CannEpiTM for supply in Australia through specialist prescribers under the Authorised Prescriber Scheme.

This is a major milestone which represents the Company’s progress towards becoming a world-leading Bio-Pharma company, with more than 10 years’ clinical experience and a leading Scientific Advisory Board in place. It also signals the immediate commencement of commercial-scale production of CannEpiTM at MXC’s EU GMP certified facility in Slovenia, and the start of revenue generation from the Company’s core pharma activity.

The formal TGA authorisation follows Human Research Ethics Committee endorsement from St Vincent’s Hospital Melbourne for the use of CannEpiTM in the treatment of adult patients with drug-resistant epilepsy.

The first batch of CannEpiTM is expected to be available for sale in Australia by December 2018, and will be distributed under the agreement with specialist Australian pharmaceutical distributor, HL Pharma.

MGC Pharmaceuticals is working with a number of Australian based specialist doctors and neurologists, who will operate under the Ethics Committee approval in place and have applied to the TGA for specific approval to prescribe CannEpi™ to their patients who suffer from drug resistant epilepsy.

Roby Zomer, Co-founder and Managing Director, MGC Pharmaceuticals commented

“We are delighted to announce the availability of our first product CannEpi™ for supply under the Authorised Prescriber Scheme. This is a significant achievement for us and we are very excited at the prospect of ramping up production to a commercial scale and bringing CannEpi™ to Australia.”

“This important step validates MXC’s seed-to-pharma strategy with the start of commercial revenues from our first Investigational Medicinal Product offering.”

Carol Ireland, Chief Executive Officer, Epilepsy Action Australia commented

“This is a significant milestone for epilepsy patients and other patient communities. It is another important step in improving access to potentially life-changing medications, and part of a global trend to recognize the valid medical benefits of cannabis.”

“As advocates of patient rights, we are pleased to see progress, and a sign that patient needs and wants are heard and respected. We believe that Australia has a chance to lead the way in this global shift and we are proud that the epilepsy community and Epilepsy Action have played a significant part in bringing this about.”

--Ends--

For further information, please contact:

Media Enquiries

Alex Liddington-Cox
Media and Capital Partners
+61 474 701 469
alex.liddingtoncox@mcpartners.com.au

MGC Pharmaceuticals Ltd

Brett Mitchell
Executive Chairman
+61 8 6382 3390
info@mgcpharma.com.au

About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is an EU based Bio-Pharma company with many years of technical clinical and commercial experience in the medical cannabis industry. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality Cannabinoids based pharmaceuticals products for the growing demand in the medical markets in Europe, North America and Australasia.

Follow us through our social media channels   